Trial Profile
A Phase II, Double-blind, Randomized, Parallel-group, Placebo- Controlled Multi-center Study to Investigate the Effect of the Adenosine A1 Receptor Antagonist PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Patients With Mild-to-moderate Persistent Atopic Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs PBF 680 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms ADENOASMA
- Sponsors Palobiofarma
- 18 Sep 2020 Status changed from recruiting to completed.
- 15 Jun 2018 Status changed from planning to recruiting.
- 13 Apr 2018 New trial record